TNFRSF8 and Hodgkins lymphoma: The report from a phase 1 trial combining H22 with Ki-4(anti-CD30) in patients with refractory Hodgkin lymphoma also presented 1 complete remission, 3 partial remissions, and 4 patients with stable disease out of a total panel of 10 patients [88].